End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 EUR | -1.00% |
|
-1.00% | -1.00% |
Jun. 17 | Neovacs: collaboration agreement with CNRS | CF |
Jun. 10 | Neovacs: presents results from vaccine candidates | CF |
Sales 2022 | 1.11K 1.21K | Sales 2023 | 533K 582K | Capitalization | 278 303.17 |
---|---|---|---|---|---|
Net income 2022 | -3M -3.27M | Net income 2023 | -8M -8.72M | EV / Sales 2022 | - |
Net cash position 2022 | 5.55M 6.06M | Net cash position 2023 | 237K 258K | EV / Sales 2023 | -0.44 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.08
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0.12% |
1 day | -1.00% |
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 20-09-30 | |
Vincent Serra
COO | Chief Operating Officer | 55 | 19-02-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 85 | 03-05-27 | |
Daniel Zagury
FOU | Founder | - | 93-04-15 |
Hugo Brugière
CEO | Chief Executive Officer | - | - |
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ALNEV Stock
- ALNEV Stock